Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
University of Colorado, Denver
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00630734CT.gov Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hyperlipidemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| NORVIR (this asset) | University of Colorado, Denver | Approved | BB · 67 |
| Atorvastatin | Poznan University of Medical Sciences | P4 | BBB |
| Rosuvastatin | Nanjing First Hospital, Nanjing Medical University | P4 | BBB |
| Pravastatin | University of North Carolina, Chapel Hill | P4 | BBB |
| Ezetimibe | NewAmsterdam Pharma | P4 | BBB |
| Darunavir | University of Colorado, Denver | P4 | BB |
| Fenofibrate | Ospedale di Circolo - Fondazione Macchi | P4 | BB |
| Inclisiran | University of California, San Diego | P4 | BB |
| Simvastatin | National University Hospital, Singapore | P4 | BB |
+27 more in the Hyperlipidemia cohort
Other indications for NORVIR
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Hepatitis C Virus Infection | — | P3 | BBB · 76 |
| Hepatitis C Virus Infection | — | P3 | BBB · 76 |
| HIV Infectious Disease | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. NORVIR in Hyperlipidemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/norvir-hyperlipidemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →